No Effect of Beta-adrenergic Blockade on Hypoglycaemic Effect of Glucagon-like Peptide-1 (GLP-1) in Normal Subjects

Diabetic Medicine

Volumn 13, Issue 6, 1996, Pages 544-548

  Toft Nielsen, M ^a,c   Hvidberg, A ^a   Hilsted, J ^a   Dige Petersen, H ^a   Holst, J J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Beta blockade; Counterregulation; Glucagon; Hepatic glucose production; Insulin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PROPRANOLOL;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG MECHANISM; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; HYPOGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANALYSIS OF VARIANCE; DRUG INTERACTIONS; EPINEPHRINE; FASTING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIA; INFUSIONS, INTRAVENOUS; INSULIN; MALE; NOREPINEPHRINE; PEPTIDE FRAGMENTS; PROPRANOLOL; PROTEIN PRECURSORS; REFERENCE VALUES;

EID: 0029898525     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199606)13:6<544::AID-DIA129>3.0.CO;2-X     Document Type: Article

References (18)

1. Ørskov C. Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 1992; 35: 701-711.
2. Holst JJ, Ørskov C. Glucagon and related peptides: In: Walsh JH, Dockray GJ, eds. Gut Peptides: Biochemistry and Physiology. New York, NY: Raven, 1993: 305-339.
3. Hvidberg A, Nielsen M-BT, Hilsted J, Ørskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 1994; 43: 104-108.
4. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 236: 1316-1322.
5. Nauck MA, Kleine N, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide-1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741-744.
6. Hvidberg A, Toft-Nielsen M, Hilsted J, Dige-Petersen H, Holst JJ. Effect of beta-adrenergic blockade on the hypoglycaemic effect of glucagon-like peptide-1 (GLP-1). (Abstract). Diabetologia 1994; 37 (suppl 1): A119.
7. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 1959; 82: 420-430.
8. 14C glucose. Recent Prog Horm Res 1963; 19: 445-488.
9. Ørskov C, Jeppesen J, Madsbad S, Holst JJ. Proglucagon products in plasma from non-insulin dependent diabetics and non-diabetic controls in the fasting state and following oral glucose and intravenous arginine. J Clin Invest 1991; 87: 415-423.
10. Holst JJ, Bersani M. Assays for peptide products of somatostatin gene expression: In: Conn PM, ed. Methods in Neurosciences, vol 5, Neuropeptide Technology. San Diego, CA: Academic Publishers, 1991: 3-22.
11. Ørskov C, Rabenhøj L, Kofod H, Wettergren A, Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994; 43: 535-539.
12. Appel E, Bayer P, Hajdu P, Palm D, Schofer J, Vihlein M. Determination of plasma catecholamines by means of radioenzymatic labelling and high pressure liquid chromatographic separation. Naunyn Schmiedebergs Arch Pharmacol 1981; 315: 233-239.
13. Klaniecki TS, Corder CN, McDonald RH Jr, Feldman JA. High-performance liquid chromatographic radioenzymatic assay for plasma catecholamines. J Lab Clin Med 1977; 90: 604-612.
14. Cryer PE. Glucose homeostasis and hypoglycaemia: In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. Philadelphia, PA: Saunders, 1992: 1223-1253.
15. Christensen NJ, Henriksen JH. Degradation of endogenous catecholamines: In: Henriksen JH, ed. Degradation of Bioactive Substances: Physiology and Pathophysiology. Boca Raton: CRC Press, 1991: 289-305.
16. Cryer PE, Rizza RA, Haymond MW, Gerich JE. Epinephrine and norepinephrine are cleared through beta-adrenergic, but not alpha-adrenergic, mechanisms in man. Metabolism 1980; 29 (suppl 1): 1114-1118.
17. Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR. The effect of propranolol on catecholamine clearance. Clin Pharmacol Ther 1986; 40: 116-119.
18. Holst JJ, Ehrhart-Bornstein M, Messell T, Poulsen SS, Harling H. Release of galanin from isolated perfused porcine adrenal glands. Role of the splanchnic nerves. Am J Physiol 1991; 261: E31-E40.